Physician profile
William Long
NPI 1730175852
$4,663.20
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $409 · 2021: $498 · 2022: $1,379 · 2023: $1,059 · 2024: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,481.06 | 2019-2024 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $701.13 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Abbvie INC. | $428.37 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $348.51 | 2019-2022 | |
| Genzyme Corporation | $273.01 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.53 | 2020-2023 | Cinryze, Cuvitru |
| Shire North American Group INC | $168.64 | 2019 | |
| Genentech USA, INC. | $163.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $160.60 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $139.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $135.39 | 2022 | |
| Kaleo, INC. | $98.79 | 2019-2022 | |
| Pfizer INC. | $90.23 | 2019-2023 | |
| Grifols USA, LLC | $85.69 | 2020-2023 | Xembify |
| Csl Behring | $45.79 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.86 | 2023 | |
| Biocryst US Sales Co., LLC | $18.06 | 2022 | |
| Alk-Abello, INC | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.